32P - Clinical correlation between different C-kit exon mutations and clinical outcome Imatinib mesylate treatment in Gist patients

Date 26 February 2019
Event ESMO Targeted Anticancer Therapies Congress 2019
Session Cocktail and Poster viewing
Topics GIST
Presenter Ghada Zakaria
Citation Annals of Oncology (2019) 30 (suppl_1): i12-i14. 10.1093/annonc/mdz026
Authors G.Y. Zakaria1, N. Allahloubi2, A. Bahnasy3, O. Khorshid2
  • 1Oncology, Cairo Oncology Center Cairo University-CairoCure, 12311 - Cairo/EG
  • 2Medical Oncology, NCI, Cairo/EG
  • 3Cancer Biology, NCI, Cairo/EG

Abstract

The clinical behavior of GISTs is highly variable. This study aims at detection of different histo-pathological tumor features and correlation with different clinical aspects after treatment with imatinib, based on C-KIT exon mutation status.